First-Line Treatment for Advanced Pancreatic Cancer
Abstract
Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options. The authors summarize four abstracts (#148, #233, #158, #291) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused on novel agents for metastatic pancreatic cancer.
Image: Logo (H. Lee Moffitt Cancer Center. Tampa, FL, USA).
Downloads
References
Cancer of the Pancreas: SEER Stat Fact Sheets,
Burris HA, 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-13, 1997
Riess H, Neuhaus P, Post S, et al: Conko-001: Final Results of the Randomized, Prospective, Multicenter Phase Iii Trial of Adjuvant Chemotherapy with Gemcitabine Versus Observation in Patients with Resected Pancreatic Cancer (Pc). Annals of Oncology 19:45-46, 2008
Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-25, 2011
Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703-13, 2012
Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548-54, 2011
Daniel D. Von Hoff TJE, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee Ma, Mansoor N. Saleh, Marion Harris, Michele Reni, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, Eric Van Cutsem, David Goldstein, Xinyu Wei, Jose Luis Iglesias, Markus Frederic Renschler; Virginia G. Piper: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 30: 2012 (suppl 34; abstr LBA148), 2013
Gael Deplanque MD, Mohamed Hebbar, Patrick J. Flynn, Bohuslav Melichar, James Atkins, Philippe Ruszniewski, Eric Raymond, Olivier Hermine, Pascal Hammel: Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. J Clin Oncol 30: 2012 (suppl 34; abstr 158), 2013
Ramesh K. Ramanathan PL, Joseph W. Leach, Stephen Patrick Anthony, Glen J. Weiss, Peter J. Rosen, Vincent J. Picozzi, Jasgit C. Sachdev, Tim Larson, Ronald Korn, Chengcheng Hu, Gayle S. Jameson, Amy C. Stoll, Daniel D. Von Hoff, John E. Seng; Virginia G. Piper: Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 233), 2013
Jeffrey R. Infante BGS, Joon Oh Park, Chung-Pin Li, Max E. Scheulen, Saifuddin M. Kasubhai, Do-Youn Oh, Yuan Liu, Soumi Lahiri, Klaudia Steplewski, Ngocdiep T. Le: A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol 30: 2012 (suppl 34; abstr 291), 2013
Neuzillet C, Hammel P, Tijeras-Raballand A, et al: Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev, 2012
Copyright (c) 2014 Nishi Kothari, Muhammad Wasif Saif, Richard Kim
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.